Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exercise-mobilized NK-enriched DLI-X to Prevent Leukemia Relapse After Allogeneic HCT
NCT07254793Phase 1Recruiting
- Sponsor
- University of Arizona
- Start
- Oct 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 1, randomised trial in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute undifferentiated leukemia (AUL) and 3 more (2 arms), sponsored by University of Arizona. Primary endpoint: Graft-versus-Host Disease-Free, Relapse-Free Survival at 3 years. Started Oct 2026; status: recruiting.
02
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)acute undifferentiated leukemia (AUL)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT07254793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07254793.